## SUPPLEMENTARY FIGURES




**Supplementary Figure S1: ELISA evaluation of soluble ligand levels in culture supernatants of docetaxel-treated tumor cells.** Soluble ULBP2 **A, B.** and MICA **C.** were evaluated in culture supernatants of BT474 (A, C) and MDAMB361 (B) cancer cells not treated (NT) or docetaxel (DTX)-treated at different time points. Data, given as mean ± SEM ($n$ = 2), were normalized on the number of cells in culture at the time of supernatant harvesting. *$p < 0.05$ by unpaired Student's $t$-test.




**Supplementary Figure S2: Western blot analysis of NKG2D ligands MICA and ULBP2 in MDAMB361 tumors.** MDAMB361 cells were xenotransplanted in SCID mice and when tumors reached a volume of 200 $mm^3$, mice were treated with docetaxel (DTX) at doses of 20 mg/Kg. At 24 hours after treatment, tumors were analyzed for expression of ADCC-associated factors.




**Supplementary Figure S3: ADCC of BT474 and MDAMB361 cells treated with docetaxel at different time points. A.** BT474 cells treated or not with 100 nM docetaxel (DTX) for 12 hours were used in trastuzumab-mediated ADCC assay with PBMC from healthy donors as effector cells ($n = 5$). **B.** Percentage of ADCC of BT474 treated as in A, in the presence or absence of NKG2D blocking antibodies. **C, D.** Percentage of ADCC of BT474 (C) and MDAMB361 **(D)** cells treated or not with 100 nM docetaxel for 72 hours is shown. *$p < 0.05$, ***$p < 0.001$ by paired Student's $t$-test.




**Supplementary Figure S4: Phenotype of circulating NK cells in mice bearing MDAMB361 tumors treated or not with docetaxel. A, B.** Analysis of the percentage of CD49b+ cells (A) and NKG2D expression of NK cells (MFI, B) in blood of mice treated or not with docetaxel. *$p < 0.05$ by unpaired Student's *t*-test.




**Supplementary Figure S5: Modulation of activating receptors on NK cells by chemotherapy in human patients. A, B, C.** PBMC isolated from patients at different time point during neoadjuvant treatment (pre: before any treatment, post: after chemotherapy) were analyzed by flow cytometry for expression of NKp30 **(A)** NKp44 **(B)** NKp46 **(C)** receptors on CD3– CD56+ NK cells. Data are shown as MFI in each patient. **D.** Percent of $CD69^+$ cells in NK cells.




**Supplementary Figure S6: ADCC increment induced by healthy donor PBMCs conditioned with pre- and post-treatment plasma from patients.**